ETODOLAC Drug Patent Profile
✉ Email this page to a colleague
When do Etodolac patents expire, and when can generic versions of Etodolac launch?
Etodolac is a drug marketed by Ani Pharms, Apotex, Biopharm, Chartwell Molecules, Ipca Labs Ltd, Mylan, Natco Pharma, Sandoz, Taro, Actavis Elizabeth, Bayshore Pharms Llc, Teva, Watson Labs Florida, Zydus Pharms, Amneal Pharms Co, Apotex Inc, Edenbridge Pharms, Ivax Sub Teva Pharms, Oxford Pharms, Pangea, Ranbaxy Labs Ltd, Shree Hari Intl, Taro Pharm Inds, and Watson Labs. and is included in thirty-nine NDAs.
The generic ingredient in ETODOLAC is etodolac. There are twenty-three drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the etodolac profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Etodolac
A generic version of ETODOLAC was approved as etodolac by PANGEA on April 11th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ETODOLAC?
- What are the global sales for ETODOLAC?
- What is Average Wholesale Price for ETODOLAC?
Summary for ETODOLAC
| US Patents: | 0 |
| Applicants: | 24 |
| NDAs: | 39 |
| Finished Product Suppliers / Packagers: | 31 |
| Raw Ingredient (Bulk) Api Vendors: | 118 |
| Clinical Trials: | 29 |
| Patent Applications: | 6,379 |
| Drug Prices: | Drug price information for ETODOLAC |
| Drug Sales Revenues: | Drug sales revenues for ETODOLAC |
| DailyMed Link: | ETODOLAC at DailyMed |
Recent Clinical Trials for ETODOLAC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Kutahya Health Sciences University | Phase 4 |
| Memorial Sloan Kettering Cancer Center | N/A |
| Apsen Farmaceutica S.A. | Phase 3 |
Pharmacology for ETODOLAC
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
Medical Subject Heading (MeSH) Categories for ETODOLAC
Anatomical Therapeutic Chemical (ATC) Classes for ETODOLAC
US Patents and Regulatory Information for ETODOLAC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | ETODOLAC | etodolac | TABLET;ORAL | 074847-002 | Apr 23, 1999 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Zydus Pharms | ETODOLAC | etodolac | TABLET, EXTENDED RELEASE;ORAL | 091134-003 | Jan 23, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Taro | ETODOLAC | etodolac | TABLET, EXTENDED RELEASE;ORAL | 076174-002 | Mar 13, 2003 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Chartwell Molecules | ETODOLAC | etodolac | TABLET;ORAL | 074841-001 | Jun 27, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Oxford Pharms | ETODOLAC | etodolac | TABLET;ORAL | 074819-001 | Feb 28, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Apotex Inc | ETODOLAC | etodolac | TABLET;ORAL | 076004-002 | Dec 3, 2002 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Edenbridge Pharms | ETODOLAC | etodolac | TABLET;ORAL | 209888-001 | Nov 30, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
